Sensulin

Developing glucose-responsive insulin to revolutionize diabetes treatment and improve lives

placeOklahoma City, Oklahoma, United States calendar_todayFounded 2011 groups5 employees language sensulin.com

Innovation

1 patent family (1 granted) — focus: Human necessities; filing pace slowing. Cited 50 times.

YearFilings
20121
20131
20141
20161
20171
20181
20201
20221

Investor mix

8 investors on record.

Investor typeCountShare
Venture capital450%
Private equity113%
Accelerator & incubator113%
Other / undisclosed225%
Coming soon